

**N.J. Sinden** has received funding to travel to conferences from GlaxoSmithKline (GSK) and Boehringer-Ingelheim. NJS has also received speaker's fees from GSK. This research was funded using educational grants from Grifols Therapeutics and GlaxoSmithKline. However, the funders had no role in the design of the study, interpretation of the results or production of the manuscript.

**R.A. Stockley** has received unconditional research funding from Talecris and fees for lecturing from GSK, AZ, Talecris, Takeda and Pfizer. He has received travel fund support from Boehringer and Talecris to attend international meetings.